OBJECTIVE: To assess the cross-sectional association of thiazolidinediones with diabetic macular edema (DME). METHODS: The cross-sectional association of DME and visual acuity with thiazolidinediones was examined by means of baseline fundus photographs and visual acuity measurements from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Visual acuity was assessed in 9690 participants in the ACCORD trial, and 3473 of these participants had fundus photographs that were centrally read in a standardized fashion by masked graders to assess DME and retinopathy from October 23, 2003, to March 10, 2006. RESULTS: Among the subsample, 695 (20.0%) people had used thiazolidinediones, whereas 217 (6.2%) people had DME. Thiazolidinedione use was not associated with DME in unadjusted (odds ratio [OR], 1.01; 95% confidence interval [CI], 0.71-1.44; P = .95) and adjusted (OR, 0.97; 95% CI, 0.67-1.40; P = .86) analyses. Significant associations with DME were found for retinopathy severity (P < .001) and age (OR, 0.97; 95% CI, 0.952-0.997; P = .03) but not for hemoglobin A(1c) (P = .06), duration of diabetes (P = .65), sex (P = .72), and ethnicity (P = .20). Thiazolidinedione use was associated with slightly greater visual acuity (0.79 letter; 95% CI, 0.20-1.38; P = .009) of uncertain clinical significance. CONCLUSIONS: In a cross-sectional analysis of data from the largest study to date, no association was observed between thiazolidinedione exposure and DME in patients with type 2 diabetes; however, we cannot exclude a modest protective or harmful association. Trial Registration clinicaltrials.gov Identifier: NCT00542178.
RCT Entities:
OBJECTIVE: To assess the cross-sectional association of thiazolidinediones with diabetic macular edema (DME). METHODS: The cross-sectional association of DME and visual acuity with thiazolidinediones was examined by means of baseline fundus photographs and visual acuity measurements from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Visual acuity was assessed in 9690 participants in the ACCORD trial, and 3473 of these participants had fundus photographs that were centrally read in a standardized fashion by masked graders to assess DME and retinopathy from October 23, 2003, to March 10, 2006. RESULTS: Among the subsample, 695 (20.0%) people had used thiazolidinediones, whereas 217 (6.2%) people had DME. Thiazolidinedione use was not associated with DME in unadjusted (odds ratio [OR], 1.01; 95% confidence interval [CI], 0.71-1.44; P = .95) and adjusted (OR, 0.97; 95% CI, 0.67-1.40; P = .86) analyses. Significant associations with DME were found for retinopathy severity (P < .001) and age (OR, 0.97; 95% CI, 0.952-0.997; P = .03) but not for hemoglobin A(1c) (P = .06), duration of diabetes (P = .65), sex (P = .72), and ethnicity (P = .20). Thiazolidinedione use was associated with slightly greater visual acuity (0.79 letter; 95% CI, 0.20-1.38; P = .009) of uncertain clinical significance. CONCLUSIONS: In a cross-sectional analysis of data from the largest study to date, no association was observed between thiazolidinedione exposure and DME in patients with type 2 diabetes; however, we cannot exclude a modest protective or harmful association. Trial Registration clinicaltrials.gov Identifier: NCT00542178.
Authors: Edwin H Ryan; Dennis P Han; Robert C Ramsay; Herbert L Cantrill; Steven R Bennett; Sundeep Dev; David F Williams Journal: Retina Date: 2006 May-Jun Impact factor: 4.256
Authors: David C Goff; Hertzel C Gerstein; Henry N Ginsberg; William C Cushman; Karen L Margolis; Robert P Byington; John B Buse; Saul Genuth; Jeffrey L Probstfield; Denise G Simons-Morton Journal: Am J Cardiol Date: 2007-04-12 Impact factor: 2.778
Authors: John B Buse; J Thomas Bigger; Robert P Byington; Lawton S Cooper; William C Cushman; William T Friedewald; Saul Genuth; Hertzel C Gerstein; Henry N Ginsberg; David C Goff; Richard H Grimm; Karen L Margolis; Jeffrey L Probstfield; Denise G Simons-Morton; Mark D Sullivan Journal: Am J Cardiol Date: 2007-04-16 Impact factor: 2.778
Authors: Emily Y Chew; Walter T Ambrosius; Letitia T Howard; Craig M Greven; Samantha Johnson; Ronald P Danis; Matthew D Davis; Saul Genuth; Michael Domanski Journal: Am J Cardiol Date: 2007-04-13 Impact factor: 2.778
Authors: Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Ramón Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray Journal: N Engl J Med Date: 2007-06-05 Impact factor: 91.245
Authors: Diana V Do; Xue Wang; Satyanarayana S Vedula; Michael Marrone; Gina Sleilati; Barbara S Hawkins; Robert N Frank Journal: Cochrane Database Syst Rev Date: 2015-01-31
Authors: Emily W Gower; James F Lovato; Walter T Ambrosius; Emily Y Chew; Ronald P Danis; Matthew D Davis; David C Goff; Craig M Greven Journal: Am J Ophthalmol Date: 2017-12-22 Impact factor: 5.258
Authors: F Bandello; J Cunha-Vaz; N V Chong; G E Lang; P Massin; P Mitchell; M Porta; C Prünte; R Schlingemann; U Schmidt-Erfurth Journal: Eye (Lond) Date: 2012-01-13 Impact factor: 3.775
Authors: Paolo S Silva; Jerry D Cavallerano; Jennifer K Sun; Lloyd M Aiello; Lloyd Paul Aiello Journal: Nat Rev Endocrinol Date: 2010-07-27 Impact factor: 43.330